281 related articles for article (PubMed ID: 23960186)
21. Correlation of CTNNB1 Mutation Status with Progression Arrest Rate in RECIST Progressive Desmoid-Type Fibromatosis Treated with Imatinib: Translational Research Results from a Phase 2 Study of the German Interdisciplinary Sarcoma Group (GISG-01).
Kasper B; Gruenwald V; Reichardt P; Bauer S; Hohenberger P; Haller F
Ann Surg Oncol; 2016 Jun; 23(6):1924-7. PubMed ID: 26861905
[TBL] [Abstract][Full Text] [Related]
22. Lower Rate of CTNNB1 Mutations and Higher Rate of APC Mutations in Desmoid Fibromatosis of the Breast: A Series of 134 Tumors.
Norkowski E; Masliah-Planchon J; Le Guellec S; Trassard M; Courrèges JB; Charron-Barra C; Terrier P; Bonvalot S; Coindre JM; Laé M
Am J Surg Pathol; 2020 Sep; 44(9):1266-1273. PubMed ID: 32590455
[TBL] [Abstract][Full Text] [Related]
23. Intraabdominal sporadic desmoid tumors and inflammation: an updated literature review and presentation and insights on pathogenesis of synchronous sporadic mesenteric desmoid tumors occurring after surgery for necrotizing pancreatitis.
Prete F; Rotelli M; Stella A; Calculli G; Sgaramella LI; Amati A; Resta N; Testini M; Gurrado A
Clin Exp Med; 2023 Jul; 23(3):607-617. PubMed ID: 35913675
[TBL] [Abstract][Full Text] [Related]
24. β-Catenin in desmoid-type fibromatosis: deep insights into the role of T41A and S45F mutations on protein structure and gene expression.
Colombo C; Belfiore A; Paielli N; De Cecco L; Canevari S; Laurini E; Fermeglia M; Pricl S; Verderio P; Bottelli S; Fiore M; Stacchiotti S; Palassini E; Gronchi A; Pilotti S; Perrone F
Mol Oncol; 2017 Nov; 11(11):1495-1507. PubMed ID: 28627792
[TBL] [Abstract][Full Text] [Related]
25. β-catenin (CTNNB1) mutations and clinicopathological features of mesenteric desmoid-type fibromatosis.
Huss S; Nehles J; Binot E; Wardelmann E; Mittler J; Kleine MA; Künstlinger H; Hartmann W; Hohenberger P; Merkelbach-Bruse S; Buettner R; Schildhaus HU
Histopathology; 2013 Jan; 62(2):294-304. PubMed ID: 23020601
[TBL] [Abstract][Full Text] [Related]
26. Does the Addition of Mutations of CTNNB1 S45F to Clinical Factors Allow Prediction of Local Recurrence in Patients With a Desmoid Tumor? A Local Recurrence Risk Model.
Pinto FFE; Mello CAL; Nakagawa SA; Chung WT; Torrezan GT; Barros BDF; Cunha IW; Calsavara VF; Carraro DM; Lopes A
Clin Orthop Relat Res; 2023 Oct; 481(10):1978-1989. PubMed ID: 37104792
[TBL] [Abstract][Full Text] [Related]
27. Immunohistochemical staining with non-phospho β-catenin as a diagnostic and prognostic tool of COX-2 inhibitor therapy for patients with extra-peritoneal desmoid-type fibromatosis.
Sakai T; Nishida Y; Hamada S; Koike H; Ikuta K; Ota T; Ishiguro N
Diagn Pathol; 2017 Aug; 12(1):66. PubMed ID: 28851389
[TBL] [Abstract][Full Text] [Related]
28. 'Difficult to diagnose' desmoid tumours: a potential role for CTNNB1 mutational analysis.
Colombo C; Bolshakov S; Hajibashi S; Lopez-Terrada L; Wang WL; Rao P; Benjamin RS; Lazar AJ; Lev D
Histopathology; 2011 Aug; 59(2):336-40. PubMed ID: 21884214
[TBL] [Abstract][Full Text] [Related]
29. Is immunohistochemical staining for β-catenin the definitive pathological diagnostic tool for desmoid-type fibromatosis? A multi-institutional study.
Koike H; Nishida Y; Kohno K; Shimoyama Y; Motoi T; Hamada S; Kawai A; Ogose A; Ozaki T; Kunisada T; Matsumoto Y; Matsunobu T; Ae K; Gokita T; Sakai T; Shimizu K; Ishiguro N
Hum Pathol; 2019 Feb; 84():155-163. PubMed ID: 30292627
[TBL] [Abstract][Full Text] [Related]
30. Lack of Prognostic Value of CTNNB1 Mutation Profile in Desmoid-Type Fibromatosis.
Penel N; Bonvalot S; Bimbai AM; Meurgey A; Le Loarer F; Salas S; Piperno-Neumann S; Chevreau C; Boudou-Rouquette P; Dubray-Longeras P; Kurtz JE; Guillemet C; Bompas E; Italiano A; Le Cesne A; Orbach D; Thery J; Le Deley MC; Blay JY; Mir O
Clin Cancer Res; 2022 Sep; 28(18):4105-4111. PubMed ID: 35294527
[TBL] [Abstract][Full Text] [Related]
31. Spatio-temporal genetic heterogeneity of CTNNB1 mutations in sporadic desmoid type fibromatosis lesions.
Doyen J; Duranton-Tanneur V; Hostein I; Karanian-Philippe M; Chevreau C; Breibach F; Coutts M; Dadone B; Saint-Paul MC; Gugenheim J; Duffaud F; Pedeutour F
Virchows Arch; 2016 Mar; 468(3):369-74. PubMed ID: 26666421
[TBL] [Abstract][Full Text] [Related]
32. Long-term Outcomes of Oral Vinorelbine in Advanced, Progressive Desmoid Fibromatosis and Influence of
Mir O; Honoré C; Chamseddine AN; Dômont J; Dumont SN; Cavalcanti A; Faron M; Rimareix F; Haddag-Miliani L; Le Péchoux C; Levy A; Court C; Briand S; Fadel E; Mercier O; Bayle A; Brunet A; Ngo C; Rouleau E; Adam J; Le Cesne A
Clin Cancer Res; 2020 Dec; 26(23):6277-6283. PubMed ID: 32873570
[TBL] [Abstract][Full Text] [Related]
33. Next-generation sequencing is highly sensitive for the detection of beta-catenin mutations in desmoid-type fibromatoses.
Aitken SJ; Presneau N; Kalimuthu S; Dileo P; Berisha F; Tirabosco R; Amary MF; Flanagan AM
Virchows Arch; 2015 Aug; 467(2):203-10. PubMed ID: 25838078
[TBL] [Abstract][Full Text] [Related]
34. Superficial fibromas with CTNNB1 mutation.
Kuntze A; Meliß RR; Ermert L; Falkenberg KD; Puller AC; Trautmann M; Hartmann W; Wardelmann E
Genes Chromosomes Cancer; 2024 May; 63(5):e23247. PubMed ID: 38757718
[TBL] [Abstract][Full Text] [Related]
35. Identification of Familial Adenomatous Polyposis carriers among children with desmoid tumours.
Kattentidt Mouravieva AA; Geurts-Giele IR; de Krijger RR; van Noesel MM; van de Ven CP; van den Ouweland AM; Kromosoeto JN; Dinjens WN; Dubbink HJ; Smits R; Wagner A
Eur J Cancer; 2012 Aug; 48(12):1867-74. PubMed ID: 22305464
[TBL] [Abstract][Full Text] [Related]
36. Analysis of β-catenin expression and exon 3 mutations in pediatric sporadic aggressive fibromatosis.
Bo N; Wang D; Wu B; Chen L; Ruixue Ma
Pediatr Dev Pathol; 2012; 15(3):173-8. PubMed ID: 21323417
[TBL] [Abstract][Full Text] [Related]
37. Correlation between beta-catenin widespread nuclear expression and matrix metalloproteinase-7 overexpression in sporadic desmoid tumors.
Matono H; Oda Y; Nakamori M; Tamiya S; Yamamoto H; Yokoyama R; Saito T; Iwamoto Y; Tsuneyoshi M
Hum Pathol; 2008 Dec; 39(12):1802-8. PubMed ID: 18715618
[TBL] [Abstract][Full Text] [Related]
38. Novel intra-genic large deletions of CTNNB1 gene identified in WT desmoid-type fibromatosis.
Colombo C; Urbini M; Astolfi A; Collini P; Indio V; Belfiore A; Paielli N; Perrone F; Tarantino G; Palassini E; Fiore M; Pession A; Stacchiotti S; Pantaleo MA; Gronchi A
Genes Chromosomes Cancer; 2018 Oct; 57(10):495-503. PubMed ID: 29901254
[TBL] [Abstract][Full Text] [Related]
39. Near universal detection of alterations in CTNNB1 and Wnt pathway regulators in desmoid-type fibromatosis by whole-exome sequencing and genomic analysis.
Crago AM; Chmielecki J; Rosenberg M; O'Connor R; Byrne C; Wilder FG; Thorn K; Agius P; Kuk D; Socci ND; Qin LX; Meyerson M; Hameed M; Singer S
Genes Chromosomes Cancer; 2015 Oct; 54(10):606-15. PubMed ID: 26171757
[TBL] [Abstract][Full Text] [Related]
40. Systemic Chemotherapies Retain Antitumor Activity in Desmoid Tumors Independent of Specific Mutations in CTNNB1 or APC: A Multi-institutional Retrospective Study.
Nathenson MJ; Hu J; Ratan R; Somaiah N; Hsu R; DeMaria PJ; Catoe HW; Pang A; Subhawong TK; Amini B; Sweet K; Feister K; Malik K; Jagannathan J; Braschi-Amirfarzan M; Sheren J; Caldas Y; Moreno Tellez C; Rosenberg AE; Lazar AJ; Maki RG; Benedetto P; Cohen J; Trent JC; Ravi V; Patel S; Wilky BA
Clin Cancer Res; 2022 Sep; 28(18):4092-4104. PubMed ID: 35180772
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
